Judith C. van Deutekom

Author

Also Known As

J C van Deutekom, J. C. v. Deutekom, J. C. van Deutekom, J.C. van Deutekom, Judith C. van Deutekom, Judith C. van Deutekom (632518), Judith CT van Deutekom

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center ProQR Therapeutics (Netherlands)BioMarin (Netherlands)KU Leuven University of Gothenburg

About

Judith C. van Deutekom is an author at Leiden University Medical Center specializing in medicine, molecular genetics, and genetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	240
2	Health Sciences	2	2	153
3	Natural Sciences	1	1	149
4	Applied Physiology	1	1	129
5	Cell Biology	1	1	149

Judith C. van Deutekom

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 Judith C. van Deutekom, Anneke A. M. Janson, Ieke B. Ginjaar, New England Journal of Medicine	2007	760
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy Nathalie Goemans, M. Tulinius, Johanna T. van den Akker, New England Journal of Medicine	2011	659
Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle Virginia Arechavala‐Gomeza, Ian R. Graham, Linda Popplewell, Human Gene Therapy Exon SkippingAntisense Oligonucleotide SequencesDuchenne Muscular DystrophyNatural SciencesMolecular Biology	2007	149
Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model Hans Heemskerk, Christa de Winter, Petra van Kuik, Molecular Therapy	2010	137
Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy Chantal Beekman, Anneke A. M. Janson, Aabed Baghat, PLoS ONE Muscle FunctionImmunologyMuscle PhysiologyKinesiologyMuscle Injury	2018	129
Dystrophin levels and clinical severity in Becker muscular dystrophy patients J.C. van den Bergen, Beatrijs Wokke, Annika Janson, Journal of Neurology Neurosurgery & Psychiatry	2013	121
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study Nathalie Goemans, M. Tulinius, M. van den Hauwe, PLoS ONE	2016	88
Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family Ieke B. Ginjaar, Alexander L.J. Kneppers, Jan-Douwe M v d Meulen, European Journal of Human Genetics Mendelian DisorderGenetic DisorderGeneticsVariable PhenotypesPathology	2000	87
Design and Analysis of Effects of Triplet Repeat Oligonucleotides in Cell Models for Myotonic Dystrophy Anchel González‐Barriga, Susan Mulders, Jeroen van de Giessen, Molecular Therapy — Nucleic Acids	2013	43
A Sensitive, Reproducible and Objective Immunofluorescence Analysis Method of Dystrophin in Individual Fibers in Samples from Patients with Duchenne Muscular Dystrophy Chantal Beekman, Jessica A. Sipkens, Janwillem Testerink, PLoS ONE	2014	42

Page 1